A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)
Phase of Trial: Phase I/II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary)
- Indications Bladder cancer
- Focus Pharmacodynamics
- 09 Jul 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 17 Sep 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2018 to 1 Oct 2018.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.